Influences of Jieyu Ruanjian Huoxue prescription on hepatic fibrosis indices and APRI in patients with hepatitis B cirrhosis.

OBJECTIVE

To investigate the influences of Jieyu Ruanjian Huoxue prescription on hepatic fibrosis indices and aspartate aminotransferase to platelet ratio index (APRI) in patients with hepatitis B cirrhosis (HBC).

METHODS

A total of 140 patients with hepatitis B complicated with cirrhosis who received treatment in our hospital from January 2019 to December 2019 were selected as the research subjects. and Accoridng to the difference of intervention methods, the patients were divided into the study group (n=80, conventional treatment combined with Jieyu Ruanjian Huoxue prescription) and the control group (n=60, conventional treatment). The clinical intervention effects, changes in hepatic fibrosis indices and hepatic function indices, and levels of inflammatory factors before and after intervention were analyzed. In addition, Pearson correlation analysis was conducted to analyze the correlation between fibrosis indices and hepatic function indices in patients with HBC.

RESULTS

The overall response rate in the study group was markedly higher than that in the control group (98.75% vs. 91.67%, P < 0.05). The levels of hyaluronic acid (HA), Type IV collagen (IV-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), APRI, interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) in the study group were lower than those in the control group (P < 0.05) during the 1-6 months of follow-up treatment. Pearson correlation analysis exhibited that hepatic fibrosis indices (HA and IV-C) were positively correlated with liver function indices (AST and ALT) (P < 0.05).

CONCLUSION

Jieyu Ruanjian Huoxue prescription can remarkably improve the hepatic fibrosis, abnormal hepatic function, and the level of inflammatory factors in patients with HBC, exhibiting a satisfactory efficacy. Therefore, Jieyu Ruanjian Huoxue prescription is worthy of clinical promotion and implementation.